Use of archived specimens in evaluation of prognostic and predictive biomarkers

Journal of the National Cancer Institute

Volumn 101, Issue 21, 2009, Pages 1446-1452

  Simon, Richard M ^a   Paik, Soonmyung ^b   Hayes, Daniel F ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

BIOASSAY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RESEARCH; COST; GENE MUTATION; HUMAN; MICROARRAY ANALYSIS; NOTE; PATHOGENESIS; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SEMANTICS; VALIDITY;

ANTINEOPLASTIC AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RETROSPECTIVE STUDIES; SELECTION BIAS; TISSUE BANKS; TUMOR MARKERS, BIOLOGICAL;

EID: 70449420123     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp335     Document Type: Note

References (28)

1. Ransohoff DE. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer. 2004; 4 ( 4 ): 309-314.
2. Henry NL, Hayes DF. Uses and abuses of tumor markers in the diagnosis, monitoring and treatment of primary and metastatic breast cancer. Oncologist. 2006; 11 ( 6 ): 541-552.
3. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996; 88 ( 20 ): 1456-1466.
4. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006; 24 ( 33 ): 5313-5327.
5. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25 ( 33 ): 5287-5310.
6. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005; 97 ( 16 ): 1180-1184. (Pubitemid 41258223)
7. Hayes D, Ethier S, Lippman M. New guidelines for reporting tumor marker studies in breast cancer research and treatment: REMARK. Breast Cancer Research and Treatment. 2006; 100 ( 1 ): 237-238.
8. Simon R. A roadmap for developing and validating therapeutically relevant genomic classifi ers. J Clin Oncol. 2005; 23 ( 29 ): 7332-7341.
9. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol. 2005; 23 ( 9 ): 2020-2027.
10. Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res. 2005; 11 ( 21 ): 7872-7878.
11. Jiang W, Freidlin B, Simon R. Biomarker adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defi ned subset effect. J Natl Cancer Inst. 2007; 99 ( 13 ): 1036-1043.
12. Simon R. Using genomics in clinical trial design. Clin Cancer Res. 2008; 14 ( 19 ): 5984-5993.
13. Simon R. Designs and adaptive analysis plans for pivotal clinical trials of therapeutics and companion diagnostics. Expert Rev Mol Diagn. 2008; 2 ( 6 ): 721-729.
14. Simon R, Wang SJ. Use of genomic signatures in therapeutics development. Pharmacogenomics J. 2006; 6 ( 3 ): 166-173.
15. Bogaerts J, Cardoso F, Buyse M, et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol. 2006; 3 ( 10 ): 540-551.
16. Sparano JA. TAILORx: Trial Assigning Individualized Options for Treatment(Rx). Clin Breast Cancer. 2008; 7 ( 4 ): 347-350.
17. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab effi cacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26 ( 10 ): 1626-1634.
18. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefi t from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359 ( 17 ): 1757-1765.
19. Hunter DJ, Khoury MJ, Drazen JM. Letting the genome out of the bottle-will we get our wish. N Engl J Med. 2008; 358 ( 2 ): 105-107.
20. Goldstein NS, Hewitt SM, Taylor CR, Yaziji H, Hicks DG. Recommendations for improved standardization of immunohistochem-istry. Appl Immunohistochem Mol Morphol. 2007; 15 ( 2 ): 124-133.
21. Goldstein NS, Hunter S, Forbes S, Odish E, Tehrani M. Estrogen receptor antibody incubation time and extent of immunoreactivity in invasive carcinoma of the breast: the importance of optimizing antibody avidity. Appl Immunohistochem Mol Morphol. 2007; 15 ( 2 ): 203-207.
22. Peterson B, George SL. Sample size requirements and length of study for testing interaction in a 1 x k factorial design when time-to-failure is the outcome. Control Clin Trials. 1993; 14 ( 6 ): 511-522.
23. Hayes DF, Thor AD, Dressler LG, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007; 357 ( 14 ): 1496-1506.
24. Martin M, Rodriguez-Lescure A, Ruiz A, et al. Randomized phase 3 trial of fl uorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst. 2008; 100 ( 11 ): 805-814.
25. Hudis C, Dang C. The taxane limbo: how low can we go? J Natl Cancer Inst. 2008; 100 ( 11 ): 761-763.
26. Labianca R, La Verde N, Garassino MC. Development and clinical indications of cetuximab. Int J Biol Markers. 2007; 22 ( 1 suppl 4 ): S40-S46.
27. Messersmith WA, Ahnen DJ. Targeting EGFR in colorectal cancer. N Engl J Med. 2008; 359 ( 17 ): 1834-1836.
28. Allegra C, Jessup JM, Somerfi eld MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy [published online ahead of print]. J Clin Oncol. 2009; 27 ( 12 ): 2091-2096.